1-10 of 10
Edwin C. Kingsley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Benjamin B. Freeman, Ben Zhang, John M. Burke, Jennifer L. Cultrera, Habte A. Yimer, Edwin C. Kingsley, Charles M. Farber, James D'Olimpio, Hui Yao, Adam Idoine, Qi An, Jeff P. Sharman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4632.
https://doi.org/10.1182/blood-2024-198250
Published: 2024
Journal Articles

A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenström Macroglobulinemia (WM)

Edwin C. Kingsley, Shannon Fabre, Motohisa Takai, Aileen Cleary Cohen, Jingjing Schneider, Jessica Li, James D'Olimpio
Journal: Blood
Blood (2023) 142 (Supplement 1): 6171.
https://doi.org/10.1182/blood-2023-172881
Published: 2023
Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin B. Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Rocco J. Crescenzo, Kunthel By, Aileen Cleary Cohen, Adam Idoine, Sudhir Manda, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6510.
https://doi.org/10.1182/blood-2023-180161
Published: 2023
Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin B. Freeman, Moshe Levy, Charles M. Farber, James D'Olimpio, Jennifer L. Cultrera, Ben Zhang, Rocco J. Crescenzo, Adam Idoine, Xiaoping Zhang, Kunthel By, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 3279.
https://doi.org/10.1182/blood-2023-174096
Published: 2023
Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin Freeman, Moshe Yair Levy, Houston Holmes, Charles M. Farber, Arvind Chaudhry, Rocco Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Kunthel By, Jane Huang, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 3655–3657.
https://doi.org/10.1182/blood-2022-159726
Published: 2022
Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Linlin Xu, Mazyar Shadman, Anusha Ponakala, Ian W. Flinn, Moshe Yair Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Aileen Cohen, Dih-Yih Chen, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9269–9271.
https://doi.org/10.1182/blood-2022-167758
Published: 2022
Journal Articles

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Kathryn S. Kolibaba, MD, Mikhail Shtivelband, MD PhD, Edwin C. Kingsley, MD, Mehdi M. Moezi, MD, Donald Richards, MD PhD, Jeffrey P. Sharman, MD, Feng Xiaoshu, MS, Megan Cannan, B.S, Rafik Fellague-Chebra, MD, Roger M. Lyons, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1500.
https://doi.org/10.1182/blood.V130.Suppl_1.1500.1500
Published: 2017
Journal Articles

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Lihua E. Budde, MD PhD, Ahmad Halwani, Christopher A. Yasenchak, Charles Michael Farber, MD PhD, John M Burke, MD, Luis E. Fayad, MD, Beata Holkova, MD, Mark Knapp, MD, Kathryn S. Kolibaba, MD, Ranjana H Advani, MD, Stephen M Ansell, MD, PhD, Dipti Patel-Donnelly, MD, Habte A. Yimer, MD, Scott E. Smith, MD PhD, Moshe Yair Levy, MD, Mahesh Seetharam, MD, David Belada, MD PhD, Donald Brooks, MD, Edwin C. Kingsley, MD, Leonard M. Klein, Nina Wagner-Johnston, MD, Katherine Ruffner, Nancy L Bartlett, MD
Journal: Blood
Blood (2016) 128 (22): 104.
https://doi.org/10.1182/blood.V128.22.104.104
Published: 2016
Journal Articles

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Andre Goy, MD, Radhakrishnan Ramchandren, MD, Nilanjan Ghosh, MD PhD, Javier Munoz, MD, David S. Morgan, MD, Nam H. Dang, MD PhD, Mark Knapp, MD, Maria Delioukina, MD, Edwin C. Kingsley, MD, Anh Tran, BS, Jerry Ping, PhD, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, Jia Ruan, MD PhD
Journal: Blood
Blood (2016) 128 (22): 473.
https://doi.org/10.1182/blood.V128.22.473.473
Published: 2016
Journal Articles

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Michael R. Savona, MD, Kathryn Kolibaba, MD, Paul Conkling, MD, Edwin C. Kingsley, MD, Carlos Becerra, MD, John Morris, MD, Robert M. Rifkin, MD, Eric Laille, MS, Amy Kellerman, BA, Stacey M. Ukrainskyj, BSN,RN, Qian Dong, MS, Barry S. Skikne, MD
Journal: Blood
Blood (2014) 124 (21): 4638.
https://doi.org/10.1182/blood.V124.21.4638.4638
Published: 2014